ponatinib
incyte,otsuka,takeda
['cml', 'ponatinib', 'pivotal']
#eha2022 #cml rw data from belgian registry on use of ponatinib in cml/ph+ve all: 5 yrs follow up. serious cardiovascular adverse events occurred in 7/77 pt (9%). efficacy comparable to pivotal studies. 
Assistant Professor @MayoCancerCare @MayoClinic Alumni @MDAndersonNews. Interest in Acute Leukemia and Chronic myeloid disorders. Views are my own